<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="other"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Adv Urol</journal-id><journal-id journal-id-type="iso-abbrev">Adv Urol</journal-id><journal-id journal-id-type="publisher-id">AU</journal-id><journal-title-group><journal-title>Advances in Urology</journal-title></journal-title-group><issn pub-type="ppub">1687-6369</issn><issn pub-type="epub">1687-6377</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">21603217</article-id><article-id pub-id-type="pmc">3095445</article-id><article-id pub-id-type="doi">10.1155/2011/804583</article-id><article-categories><subj-group subj-group-type="heading"><subject>Clinical Study</subject></subj-group></article-categories><title-group><article-title>Clinical Feature of Men Who Benefit from Dose Escalation of Naftopidil for Lower Urinary Tract Symptoms: A Prospective Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Mizusawa</surname><given-names>Takaki</given-names></name><xref ref-type="aff" rid="I1">
<sup>1, 2</sup>
</xref><xref ref-type="aff" rid="I2">
</xref></contrib><contrib contrib-type="author"><name><surname>Hara</surname><given-names>Noboru</given-names></name><xref ref-type="aff" rid="I1">
<sup>1, 2</sup>
</xref><xref ref-type="aff" rid="I2">
</xref><xref ref-type="corresp" rid="cor1">*</xref></contrib><contrib contrib-type="author"><name><surname>Obara</surname><given-names>Kenji</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Isahaya</surname><given-names>Etsuko</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Nakagawa</surname><given-names>Yuki</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Takahashi</surname><given-names>Kota</given-names></name><xref ref-type="aff" rid="I1">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="I1"><sup>1</sup>Division of Urology, Department of Regenerative and Transplant Medicine, Graduate School of Medical and Dental Sciences, Niigata University, Asahimachi 1, Niigata 951-8510, Japan</aff><aff id="I2"><sup>2</sup>Department of Urology, Kido Hospital, Niigata, Kamikido 5, Niigata 950-0891, Japan</aff><author-notes><corresp id="cor1">*Noboru Hara: <email>harasho@med.niigata-u.ac.jp</email></corresp><fn fn-type="other"><p>Academic Editor: Flavio Trigo Rocha</p></fn></author-notes><pub-date pub-type="ppub"><year>2011</year></pub-date><pub-date pub-type="epub"><day>5</day><month>4</month><year>2011</year></pub-date><volume>2011</volume><elocation-id>804583</elocation-id><history><date date-type="received"><day>10</day><month>12</month><year>2010</year></date><date date-type="rev-recd"><day>31</day><month>1</month><year>2011</year></date><date date-type="accepted"><day>11</day><month>2</month><year>2011</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2011 Takaki Mizusawa et al.</copyright-statement><copyright-year>2011</copyright-year><license xlink:href="https://creativecommons.org/licenses/by/3.0/"><license-p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><p>
<italic>Objectives</italic>. To examine the feature of men who benefit from dose escalation of naftopidil for lower urinary tract symptoms (LUTSs). <italic>Methods</italic>. Based on the IPSS, men reporting LUTS were prospectively studied using 50&#x02009;mg/day of naftopidil for the first 4 weeks; satisfied patients continued its 50&#x02009;mg/day (<italic>n</italic> = 11), and those reporting unsatisfactory improvement received its 75&#x02009;mg/day (<italic>n</italic> = 35) for the next 4 weeks. <italic>Results</italic>. The 75&#x02009;mg group showed improvement in the total IPSS and QOL score in a dose-dependent manner (at 4 weeks: <italic>P</italic> &#x0003c; .001, at 4 weeks versus 8 weeks: <italic>P</italic> &#x0003c; .05). In the 50&#x02009;mg group, both scores reduced at 4 weeks, thereafter unchanged. The baseline slow stream score alone was higher in the 75&#x02009;mg group (<italic>P</italic> = .013). The rate of change in the QOL score during the initial 4 weeks (&#x00394;QOL) and &#x00394;nocturia was smaller in the 75&#x02009;mg group (<italic>P</italic> &#x0003c; .05). <italic>Conclusions</italic>. Men with high slow stream score and unsatisfactory improvement in nocturia may benefit from dose escalation of naftopidil.</p></abstract></article-meta></front><body><sec id="sec1"><title>1. Introduction</title><p>Lower urinary tract symptoms (LUTSs) impair the health-related quality of life (QOL) [<xref rid="B1" ref-type="bibr">1</xref>&#x02013;<xref rid="B4" ref-type="bibr">4</xref>]. The prevalence and severity of LUTS increase with age, and many middle-aged to elderly people show various levels of LUTS [<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B5" ref-type="bibr">5</xref>]. Voiding symptoms are more popular in men than in women [<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>], and, correspondingly, the causative condition associated with male LUTS is represented by benign prostatic hyperplasia (BPH). The treatment theory for BPH is thus targeting voiding symptoms mainly based on two types of lower urinary tract obstruction: mechanical urinary tract obstruction by the enlarged prostate and functional constriction of the urethral and prostatic smooth muscle via sympathetic <italic>&#x003b1;</italic>
<sub>1</sub>-stimulants/<italic>&#x003b1;</italic>
<sub>1</sub>-adrenoreceptors interaction. Accordingly, <italic>&#x003b1;</italic>
<sub>1</sub>-adrenoreceptor antagonists are widely applied as the first-line in current therapeutic practice for BPH. On the other hand, it is also important to manage not only voiding symptoms but also storage symptoms in men with LUTS. Alpha<sub>1</sub>-adrenoceptor antagonists have also been known to alleviate storage symptoms, although the mechanism of storage symptoms as well as how mentioned agents are involved in improvement of them has not been fully elucidated [<xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B8" ref-type="bibr">8</xref>].</p><p>Naftopidil has a high affinity for <italic>&#x003b1;</italic>
<sub>1D</sub>-adrenoceptor; <italic>&#x003b1;</italic>
<sub>1</sub>-adrenoceptor antagonists with high selectivity for <italic>&#x003b1;</italic>
<sub>1A</sub>-adrenoceptors has been thought to be more effective in treatment of LUTS [<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>], whereas recent basic and clinical studies also showed the therapeutic potential of <italic>&#x003b1;</italic>
<sub>1</sub>-adrenoceptor antagonists with high selectivity for <italic>&#x003b1;</italic>
<sub>1D</sub>-adrenoceptors [<xref rid="B10" ref-type="bibr">10</xref>]. Indeed, naftopidil has been applied for men having BPH-associated LUTS and has been regarded as a second-generation <italic>&#x003b1;</italic>
<sub>1</sub>-adrenoceptor antagonist [<xref rid="B11" ref-type="bibr">11</xref>]. While <italic>&#x003b1;</italic>
<sub>1A</sub>-adrenoceptors play a critical role in relaxing smooth muscle of the prostate and urethra and improve obstructive/voiding symptoms [<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>], storage and bladder irritability symptoms are predominantly <italic>&#x003b1;</italic>
<sub>1D</sub>-adrenoceptor-associated conditions [<xref rid="B10" ref-type="bibr">10</xref>]. Although unfavorable/adverse effects by naftopidil on blood pressure/cardiovascular system are infrequent, 50&#x02009;mg/day of peroral naftopidil is the initial treatment setting in Asian populations generally [<xref rid="B11" ref-type="bibr">11</xref>]. A recent case-control study reported that the setting of 75&#x02009;mg/day showed a higher therapeutic efficacy compared with that of 25 or 50&#x02009;mg/day of naftopidil [<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B12" ref-type="bibr">12</xref>]. Yet, there have been few studies that examined the treatment efficacy and safety of 75&#x02009;mg/day of peroral naftopidil in longitudinal comparison with those of 50&#x02009;mg/day; such approach may possibly characterize patients who benefit from dose escalation of naftopidil without compromising safety in clinical practice. Thereby, key/leading symptoms or factors impairing LUTS-related QOL may be underscored. In the present study, we prospectively studied men having moderate-to-severe LUTS in a longitudinal approach with dose escalation from 50&#x02009;mg to 75&#x02009;mg of naftopidil once a day to examine the feature of patients who prefer and benefit from dose escalation of naftopidil, and to identify which symptom and improvement thereof reflect the LUTS-related QOL.</p></sec><sec id="sec2"><title>2. Methods</title><sec sec-type="subsection" id="sec2.1"><title>2.1. Patients</title><p>In total, 53 patients who presented at Niigata University Hospital and associated institutions with the International Prostate Symptom Score (IPSS) of 8 or higher were prospectively enrolled between September 2007 and July 2009. The performance status was good (World Health Organization Performance Status Score zero) in all of them. The study had a longitudinal design, and the procedure for this research project was approved by the Ethics Committee of our institution. Informed consent was obtained from all of the patients. Exclusion criteria were patients with a history of bladder cancer, prostate cancer, or pelvic irradiation, along with those diagnosed with bladder stone, untreated definite urinary tract infections, and neurogenic bladder. Patients who had already been treated for lower urinary tract dysfunctions with surgery or any intervention were also excluded.</p></sec><sec sec-type="subsection" id="sec2.2"><title>2.2. Examinations and Questionnaires</title><p>At the initial visit, the patients filled in the baseline International Prostate Symptom Score (IPSS) sheets handed to them when visiting the outpatient clinic. General blood and biochemical examinations, urinalysis, residual urine volume measurement using an ultrasonographic instrument, and ultrasonographic examinations of the upper and lower urinary tracts were performed in all patients. Those with microscopic hematuria received a urinary cytological examination; all of them showed a normal smear.</p></sec><sec sec-type="subsection" id="sec2.3"><title>2.3. Dose Escalation of Naftopidil and Longitudinal Assessment of IPSS</title><p>All patients were treated with 50&#x02009;mg of naftopidil once a day for the first 4 weeks and reported the IPSS after administration. Patients without adverse events who reported unsatisfactory improvement of LUTS and preferred advanced treatment based on a question &#x0201c;are you satisfied with your current urinary state, yes or no?&#x0201d; received 75&#x02009;mg of naftopidil once a day for the next 4 weeks (75&#x02009;mg group) and reported the IPSS again following treatment (8 weeks after starting treatment). Those having satisfactory improvement with the initial treatment at 50&#x02009;mg/day continued 50&#x02009;mg of naftopidil (50&#x02009;mg group) and also reported IPSS in the next 4 weeks (8 weeks after starting treatment). Adverse events were assessed at every visit.</p></sec><sec sec-type="subsection" id="sec2.4"><title>2.4. Statistical Analysis</title><p>In addition to the chi-square test and pared <italic>t</italic>-test, the Welch-corrected <italic>t</italic>-test was used to compare unpaired parameters between two subgroups, and Tukey's honestly significant difference (HSD) was used for the comparison of values among 3 or more subgroups. Correlations between parameters were analyzed using Spearman's rank correlation coefficient analysis (rs). Multilinear logistic regression model, which produces prediction formula with a smaller margin of error, was used for the identification of independent significant correlations among continuous or stepwise variables. The test was two-sided, and <italic>P</italic> &#x0003c; .05 was considered significant. All analyses were performed using SPSS version 11.0J (SPSS Inc., Chicago, IL, USA) in a Windows-based computer.</p></sec></sec><sec id="sec3"><title>3. Results</title><sec sec-type="subsection" id="sec3.1"><title>3.1. Adverse Events and Patients' Demographics</title><p>Data were available in 53 patients, and, of these, treatment was discontinued due to adverse effects at the dose of 50&#x02009;mg/day and 75&#x02009;mg/day in 5 and 2 patients (9.4% and 5.4%), respectively, at 50&#x02009;mg: dizziness in 2, slight stagger in 1, orthostatic hypotension in 1, and orthostatic syncope in 1, and the events soon disappeared by drug discontinuation; at 75&#x02009;mg, 2 patients reported slight stagger, and these disappeared soon after dose reduction to 50&#x02009;mg. Excluding these subjects, 46 patients comprised the final study groups, and 35 and 11 men were included in the 75&#x02009;mg and 50&#x02009;mg groups, respectively. Demographics and the baseline IPSS of the patients were shown in <xref ref-type="table" rid="tab1">Table 1</xref>. Patients' age, prostate volume, residual urine volume, total IPSS, and storage, voiding, and quality-of-life (QOL) scores were equally distributed between the 75&#x02009;mg and 50&#x02009;mg groups (<xref ref-type="table" rid="tab1">Table 1</xref>). For each domain of the baseline IPSS, the score for slow stream alone was higher in the 75&#x02009;mg group than in the 50&#x02009;mg group (3.6 &#x000b1; 1.6 versus 2.1 &#x000b1; 1.9, <italic>P</italic> = .013).</p></sec><sec sec-type="subsection" id="sec3.2"><title>3.2. Alteration of the IPSS and QOL Score during the Observation Period</title><p>The alteration of the total IPSS, storage score, voiding score, postmicturition score (domain for feeling of incomplete emptying), and QOL score was presented in Figures <xref ref-type="fig" rid="fig1">1(a)</xref>&#x02013;<xref ref-type="fig" rid="fig1">1(e)</xref>. The 75&#x02009;mg group showed improvement in all of these in a time-dependent and dose-dependent manner (baseline versus 4 weeks after treatment: <italic>P</italic> &#x0003c; .001 in all; 4 weeks after treatment versus 8 weeks after treatment: <italic>P</italic> = .019, <italic>P</italic> = .057, <italic>P</italic> = .047, <italic>P</italic> = .057, and <italic>P</italic> = .003, resp.), although the difference in the storage and postmicturition scores were of borderline significance between at 4 weeks and 8 weeks (Figures <xref ref-type="fig" rid="fig1">1(b)</xref> and <xref ref-type="fig" rid="fig1">1(d)</xref>). In the 50&#x02009;mg group, all of these scores reduced 4 weeks after treatment compared with those at baseline (<italic>P</italic> = .004, <italic>P</italic> = .015, <italic>P</italic> = .020, <italic>P</italic> = .041, and <italic>P</italic> &#x0003c; .001, resp.); these scores were not different between 4 weeks and 8 weeks after treatment (Figures <xref ref-type="fig" rid="fig1">1(a)</xref>&#x02013;<xref ref-type="fig" rid="fig1">1(e)</xref>), although the difference was of borderline significance regarding the QOL score (<italic>P</italic> = .053).</p></sec><sec sec-type="subsection" id="sec3.3"><title>3.3. Analyses Concerning the Feature of the 75&#x02009;mg Group</title><p>We further studied the clinical feature of men in the 75&#x02009;mg group in comparison with the 50&#x02009;mg group to identify those who benefit from 75&#x02009;mg treatment. We hypothesized that the low degree of satisfaction concerning some specific symptoms with 50&#x02009;mg/day of naftopidil might be associated with the motive for patients to select the dose escalation. We first verified that the rate of change in the QOL score during the initial 4 weeks (&#x00394;QOL) in the 75&#x02009;mg group was smaller than that in the 50&#x02009;mg group (<italic>P</italic> = .045, <xref ref-type="fig" rid="fig2">Figure 2</xref>, right side columns). We subsequently analyzed the rate of change in each domain of the IPSS during the initial 4 weeks to examine which &#x00394; domain potentially reflected &#x00394;QOL, and found that the rate of change in nocturia (&#x00394;nocturia) alone was smaller in the 75&#x02009;mg group than in the 50&#x02009;mg group (<italic>P</italic> = .046, <xref ref-type="fig" rid="fig2">Figure 2</xref>). With Spearman's rank correlation coefficient analysis, the baseline score for nocturia was correlated with the QOL score in the overall patients (rs. = 0.459, <italic>P</italic> = .002) and in the 75&#x02009;mg group (rs. = 0.462, <italic>P</italic> = .007), but the relationship was not significant in the 50&#x02009;mg group despite the high correlation coefficient (rs. = 0.482, <italic>P</italic> = .127). The score for nocturia 4 weeks after treatment was also correlated with the QOL score in the overall patients (rs. = 0.459, <italic>P</italic> = .002) and in the 75&#x02009;mg group (rs. = 0.475, <italic>P</italic> = .006); the relationship was not significant in the 50&#x02009;mg group with the high correlation coefficient (rs. = 0.508, <italic>P</italic> = .108). &#x00394;nocturia was correlated with &#x00394;QOL in the overall patients (rs. = 0.562, <italic>P</italic> &#x0003c; .001) and both in the 75&#x02009;mg and 50&#x02009;mg groups (rs. = 0.437, <italic>P</italic> = .011 and rs. = 0.663, <italic>P</italic> = .036, resp.). With multivariate analysis employing multilinear logistic regression model, &#x00394;nocturia alone was an independent value correlated with &#x00394;QOL in all 46 patients (<italic>r</italic> = 0.542, <italic>P</italic> = .006). In each group, however, this model failed to identify significant independent correlations (data not shown).</p></sec></sec><sec id="sec4"><title>4. Discussion</title><p>Funahashi and colleagues reported the efficacy of 75&#x02009;mg/day of naftopidil in patients with BPH who did not show improvement with 50&#x02009;mg/day of naftopidil [<xref rid="B12" ref-type="bibr">12</xref>]. In their study, 40 of the 122 patients received 75&#x02009;mg/day of naftopidil; prostate volume of the 9 responders was larger than that of the 31 nonresponders, and the authors concluded possible advantage of the dose escalation to 75&#x02009;mg/day of naftopidil in patients with BPH. The present study design was similar to that of Funahashi et al. [<xref rid="B12" ref-type="bibr">12</xref>], but, in our study, a higher fraction of patients (76%) experienced dose escalation based on the satisfaction in improvement of LUTS. We showed that the total IPSS, storage, voiding, postmicturition, and QOL scores in the 75&#x02009;mg group decreased in a time-dependent and dose-dependent manner, although the difference in the postmicturition and storage scores was of borderline significance between at 4 weeks and 8 weeks (<xref ref-type="fig" rid="fig1">Figure 1(a)</xref>&#x02013;<xref ref-type="fig" rid="fig1">1(e)</xref>). In the 50&#x02009;mg group, these scores were similar between 4 weeks and 8 weeks after treatment, possibly suggesting dose-dependent rather than time-dependent effects of naftopidil in the 75&#x02009;mg group; the number of patients enrolled in the 50&#x02009;mg group was small to draw a definite conclusion. Additionally, adverse effects did not differ between the two settings, supporting the safety of 75&#x02009;mg/day of this agent.</p><p>The present results showed that patients selecting 75&#x02009;mg therapy had higher scores for the slow stream domain at baseline (mean 3.6, <xref ref-type="table" rid="tab1">Table 1</xref>), and those with a baseline score of 3 or higher for slow stream are probably feasible candidates who benefit from dose escalation of naftopidil. Additionally, the 75&#x02009;mg group seemingly had a higher IPSS voiding score at baseline and larger prostate volume than the 50&#x02009;mg group; the small number of patients in the 50&#x02009;mg group might lead to the bias. Thus, it is suggested that severer bladder outlet resistance was associated with unsatisfactory improvement of symptoms during 50&#x02009;mg treatment in the 75&#x02009;mg group. Naftopidil also has an <italic>&#x003b1;</italic>
<sub>1A</sub>-adrenogenic activity, although it is weaker than that of other <italic>&#x003b1;</italic>
<sub>1</sub>-adrenoreceptor antagonists such as tamsulosin. Naftopidil is <italic>&#x003b1;</italic>
<sub>1</sub>-adrenoreceptor selective in the order of <italic>&#x003b1;</italic>
<sub>1D </sub>&#x0003e; <italic>&#x003b1;</italic>
<sub>1A </sub>&#x02265; <italic>&#x003b1;</italic>
<sub>1B</sub>, and it has about 3-fold selectivity for <italic>&#x003b1;</italic>
<sub>1D</sub>-adrenoreceptors compared with that for <italic>&#x003b1;</italic>
<sub>1A</sub>-adrenoreceptors [<xref rid="B8" ref-type="bibr">8</xref>], suggesting that dose escalation of naftopidil possibly could evoke more <italic>&#x003b1;</italic>
<sub>1A</sub>-adrenoreceptor reactions in relaxing the prostate/urethra smooth muscle and alleviating voiding symptoms. For men with bladder outlet obstruction or reporting moderate-to-severe voiding symptoms, the initial appropriate dose of naftopidil may be 75&#x02009;mg/day. </p><p>Our study also suggested the dose-dependent efficacy of naftopidil for storage symptoms in the 75&#x02009;mg groups (<xref ref-type="fig" rid="fig1">Figure 1(b)</xref>), although the difference was of borderline significance between 4 weeks and 8 weeks after treatment. Interestingly, analyses for the degree of satisfaction showed that &#x00394;QOL during the first 4 weeks with 50&#x02009;mg/day of naftopidil in the 75&#x02009;mg group was smaller than that in the 50&#x02009;mg group (<italic>P</italic> = .045, <xref ref-type="fig" rid="fig2">Figure 2</xref>) and that &#x00394;nocturia during the first 4 weeks may possibly be an important parameter for the degree of satisfaction (<italic>P</italic> = .046, <xref ref-type="fig" rid="fig2">Figure 2</xref>). We moreover verified the correlation between the QOL and nocturia scores at baseline or 4 weeks after 50&#x02009;mg treatment with Spearman's rank correlation coefficient analysis in the overall patients and 75&#x02009;mg group, but it was not significant in the 50&#x02009;mg group. We could not draw a definite conclusion concerning this result in the 50&#x02009;mg group due to the small number of patients, however; &#x00394;nocturia was correlated with &#x00394;QOL both in the 75&#x02009;mg and 50&#x02009;mg groups (rs. = 0.437, <italic>P</italic> = .011 and rs. = 0.663, <italic>P</italic> = .036, resp.). These results also suggest the possible importance of improvement in nocturia for improvement in QOL by naftopidil. Effectiveness of naftopidil at a high dose for voiding symptoms can be explained by pharmacokinetics/pharmacodynamics of the agent in vivo and its effect on <italic>&#x003b1;</italic>
<sub>1</sub>-adrenoceptor antagonists/<italic>&#x003b1;</italic>
<sub>1</sub>-adrenoreceptors interaction [<xref rid="B13" ref-type="bibr">13</xref>]. Storage symptoms are considered to represent those of BPH-related overactive bladder [<xref rid="B14" ref-type="bibr">14</xref>], and most recent basic studies on <italic>&#x003b1;</italic>
<sub>1</sub>-adrenoceptor antagonists/<italic>&#x003b1;</italic>
<sub>1</sub>-adrenoreceptors in the lower urinary tract may account for the dose-dependent efficacy of naftopidil for improving storage symptoms [<xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B15" ref-type="bibr">15</xref>]. Unfortunately, our study cannot clarify the reason for improved storage symptoms including nocturia with naftopidil; the complexity of the mechanism of nocturia made us refrain from explicating this phenomenon [<xref rid="B16" ref-type="bibr">16</xref>]. The smaller voiding score and prostate volume in the 50&#x02009;mg group suggests another possible difference in the etiology of LUTS between the two groups; LUTS in the 50&#x02009;mg group may be associated with bladder-related conditions. As described elsewhere, naftopidil is an agent with relatively high selectivity for <italic>&#x003b1;</italic>
<sub>1D</sub>-adrenoreceptors [<xref rid="B17" ref-type="bibr">17</xref>]. It has been reported that not only <italic>&#x003b1;</italic>
<sub>1A</sub>- but also <italic>&#x003b1;</italic>
<sub>1D</sub>-adrenoreceptor antagonists effectively treat male LUTS and BPH-related symptoms, but the <italic>&#x003b1;</italic>
<sub>1D</sub>-relevant mechanism has not been fully elucidated. Urinary-function-related <italic>&#x003b1;</italic>
<sub>1D</sub>-adrenoreceptors are distributed in the prostate, bladder, and spinal cord [<xref rid="B17" ref-type="bibr">17</xref>]. Alpha<sub>1</sub>-adrenoreceptors most frequently expressed in the human bladder are the <italic>&#x003b1;</italic>
<sub>1D</sub>-type, which has recently been regarded as an important subtype associated with LUTS [<xref rid="B17" ref-type="bibr">17</xref>]. In a bladder outlet obstruction model using rats, the increase in bladder detrusor muscle was associated with the higher expression of <italic>&#x003b1;</italic>
<sub>1D</sub>-adrenoreceptors both in mRNA and protein levels [<xref rid="B18" ref-type="bibr">18</xref>]. In another study on the central nervous system, intrathecally injected naftopidil reduced the intensity of bladder constriction in rats, suggesting the relevance of <italic>&#x003b1;</italic>
<sub>1D</sub>-adrenoreceptors in the spinal cord center [<xref rid="B19" ref-type="bibr">19</xref>]. With frequency/volume analysis and filling cystometry in <italic>&#x003b1;</italic>
<sub>1D</sub> knockout mice, Chen and colleagues reported that <italic>&#x003b1;</italic>
<sub>1D</sub>-adrenoreceptor subtype plays a critical role in regulating bladder function, theoretically supporting clinical observations such as effectiveness of naftopidil for treating storage symptoms [<xref rid="B20" ref-type="bibr">20</xref>]. Further clinical and basic approaches are thus warranted to elucidate the various effects of this agent.</p><p>The present study had several limitations. The small number of participants in the current study led to a limited capacity. Randomized double-blind studies in a large volume could have provided higher data quality supported by a higher evidence level. Also, studies on pharmacokinetics/pharmacodynamics were not performed in our study.</p><p>In conclusion, the present study with dose escalation from 50&#x02009;mg/day to 75&#x02009;mg/day of naftopidil showed that 75&#x02009;mg/day of naftopidil was useful for alleviating storage, voiding, and postmicturition symptoms in men without compromising safety. The high score for slow stream at baseline and unsatisfactory improvement in nocturia with 50&#x02009;mg/day of naftopidil may be important factors for men with LUTS, who prefer and benefit from dose escalation of this agent. Further studies are warranted to elucidate the various effects of naftopidil for male LUTS.</p></sec><sec id="sec5"><title> Conflict of Interests </title><p>The authors declare no conflict of interests. This work has not been funded by any commercial company or organization. </p></sec></body><back><ack><title>Acknowledgment</title><p>The authors thank Ms. Noriko Sekine, Ms. Emiko Sato, Ms. Chieko Watanabe, and Ms. Eiko Honma for their enthusiastic nursing and assistance in data acquisition.</p></ack><glossary><title>Abbreviations</title><def-list><def-item><term>LUTS:</term><def><p>Lower urinary tract symptoms</p></def></def-item><def-item><term>BPH:</term><def><p>Benign prostatic hyperplasia</p></def></def-item><def-item><term>IPSS:</term><def><p>International Prostate Symptom Score.</p></def></def-item></def-list></glossary><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abrams</surname><given-names>P</given-names></name></person-group><article-title>New words for old: lower urinary tract symptoms for &#x0201c; prostatism&#x0201d;</article-title><source><italic>British Medical Journal</italic></source><year>1994</year><volume>308</volume><issue>6934</issue><fpage>929</fpage><lpage>930</lpage><pub-id pub-id-type="pmid">8173393</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abrams</surname><given-names>P</given-names></name><name><surname>Cardozo</surname><given-names>L</given-names></name><name><surname>Fall</surname><given-names>M</given-names></name><etal/></person-group><article-title>The standardisation of terminology of lower urinary tract function: report from the standardisation sub-committee of the international continence society</article-title><source><italic>Neurourology and Urodynamics</italic></source><year>2002</year><volume>21</volume><issue>2</issue><fpage>167</fpage><lpage>178</lpage><pub-id pub-id-type="pmid">11857671</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyle</surname><given-names>P</given-names></name><name><surname>Robertson</surname><given-names>C</given-names></name><name><surname>Mazzetta</surname><given-names>C</given-names></name><etal/></person-group><article-title>The prevalence of lower urinary tract symptoms in men and women in four centres. The UrEpik study</article-title><source><italic>BJU International</italic></source><year>2003</year><volume>92</volume><issue>4</issue><fpage>409</fpage><lpage>414</lpage><pub-id pub-id-type="pmid">12930430</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mittmann</surname><given-names>N</given-names></name><name><surname>Trakas</surname><given-names>K</given-names></name><name><surname>Risebrough</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>BA</given-names></name></person-group><article-title>Utility scores for chronic conditions in a community-dwelling population</article-title><source><italic>PharmacoEconomics</italic></source><year>1999</year><volume>15</volume><issue>4</issue><fpage>369</fpage><lpage>376</lpage><pub-id pub-id-type="pmid">10537955</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Girman</surname><given-names>CJ</given-names></name><name><surname>Jacobsen</surname><given-names>SJ</given-names></name><name><surname>Tsukamoto</surname><given-names>T</given-names></name><etal/></person-group><article-title>Health-related quality of life associated with lower urinary tract symptoms in four countries</article-title><source><italic>Urology</italic></source><year>1998</year><volume>51</volume><issue>3</issue><fpage>428</fpage><lpage>436</lpage><pub-id pub-id-type="pmid">9510348</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Irwin</surname><given-names>DE</given-names></name><name><surname>Milsom</surname><given-names>I</given-names></name><name><surname>Hunskaar</surname><given-names>S</given-names></name><etal/></person-group><article-title>Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study</article-title><source><italic>European Urology</italic></source><year>2006</year><volume>50</volume><issue>6</issue><fpage>1306</fpage><lpage>1315</lpage><pub-id pub-id-type="pmid">17049716</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Homma</surname><given-names>Y</given-names></name><name><surname>Yamaguchi</surname><given-names>O</given-names></name><name><surname>Hayashi</surname><given-names>K</given-names></name></person-group><article-title>Epidemiologic survey of lower urinary tract symptoms in Japan</article-title><source><italic>Urology</italic></source><year>2006</year><volume>68</volume><issue>3</issue><fpage>560</fpage><lpage>564</lpage><pub-id pub-id-type="pmid">16979726</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takei</surname><given-names>RI</given-names></name><name><surname>Ikegaki</surname><given-names>I</given-names></name><name><surname>Shibata</surname><given-names>K</given-names></name><name><surname>Tsujimoto</surname><given-names>G</given-names></name><name><surname>Asano</surname><given-names>T</given-names></name></person-group><article-title>Naftopidil, a novel <italic>&#x003b1;</italic>-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human <italic>&#x003b1;</italic>-adrenoceptors</article-title><source><italic>Japanese Journal of Pharmacology</italic></source><year>1999</year><volume>79</volume><issue>4</issue><fpage>447</fpage><lpage>454</lpage><pub-id pub-id-type="pmid">10361884</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akiyama</surname><given-names>K</given-names></name><name><surname>Noto</surname><given-names>H</given-names></name><name><surname>Nishizawa</surname><given-names>O</given-names></name><etal/></person-group><article-title>Effect of KMD-3213, an <italic>&#x003b1;</italic>-adrenoceptor antagonist, on the prostatic urethral pressure and blood pressure in male decerebrate dogs</article-title><source><italic>International Journal of Urology</italic></source><year>2001</year><volume>8</volume><issue>4</issue><fpage>177</fpage><lpage>183</lpage><pub-id pub-id-type="pmid">11260350</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishino</surname><given-names>Y</given-names></name><name><surname>Masue</surname><given-names>T</given-names></name><name><surname>Miwa</surname><given-names>K</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Ishihara</surname><given-names>S</given-names></name><name><surname>Deguchi</surname><given-names>T</given-names></name></person-group><article-title>Comparison of two <italic>&#x003b1;</italic>-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study</article-title><source><italic>BJU International</italic></source><year>2006</year><volume>97</volume><issue>4</issue><fpage>747</fpage><lpage>751</lpage><pub-id pub-id-type="pmid">16536766</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yasuda</surname><given-names>K</given-names></name><name><surname>Yamanishi</surname><given-names>T</given-names></name><name><surname>Tojo</surname><given-names>M</given-names></name><name><surname>Nagashima</surname><given-names>K</given-names></name><name><surname>Akimoto</surname><given-names>S</given-names></name><name><surname>Shimazaki</surname><given-names>J</given-names></name></person-group><article-title>Effect of naftopidil on urethral obstruction in benign prostatic hyperplasia: assessment by urodynamic studies</article-title><source><italic>Prostate</italic></source><year>1994</year><volume>25</volume><issue>1</issue><fpage>46</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">7517541</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Funahashi</surname><given-names>Y</given-names></name><name><surname>Hattori</surname><given-names>R</given-names></name><name><surname>Matsukawa</surname><given-names>Y</given-names></name><name><surname>Komatsu</surname><given-names>T</given-names></name><name><surname>Sassa</surname><given-names>N</given-names></name><name><surname>Gotoh</surname><given-names>M</given-names></name></person-group><article-title>Clinical efficacy of a loading dose of naftopidil for patients with benign prostate hyperplasia</article-title><comment><italic>World Journal of Urology</italic>. In press</comment></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kojima</surname><given-names>Y</given-names></name><name><surname>Sasaki</surname><given-names>S</given-names></name><name><surname>Hayashi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Correlation between alpha 1-adrenoreceptor subtype mRNA expression level and efficacy of naftopidil for BPH patients</article-title><source><italic>Journal of Urology</italic></source><year>2004</year><volume>171</volume><fpage>p. 242</fpage></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komiya</surname><given-names>A</given-names></name><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Awa</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Clinical effect of naftopidil on the quality of life of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a prospective study</article-title><source><italic>International Journal of Urology</italic></source><year>2010</year><volume>17</volume><issue>6</issue><fpage>555</fpage><lpage>562</lpage><pub-id pub-id-type="pmid">20370847</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwinn</surname><given-names>DA</given-names></name><name><surname>Roehrborn</surname><given-names>CG</given-names></name></person-group><article-title>
<italic>&#x003b1;</italic>-Adrenoceptor subtypes and lower urinary tract symptoms</article-title><source><italic>International Journal of Urology</italic></source><year>2008</year><volume>15</volume><issue>3</issue><fpage>193</fpage><lpage>199</lpage><pub-id pub-id-type="pmid">18304211</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>FitzGerald</surname><given-names>MP</given-names></name><name><surname>Litman</surname><given-names>HJ</given-names></name><name><surname>Link</surname><given-names>CL</given-names></name><name><surname>McKinlay</surname><given-names>JB</given-names></name></person-group><article-title>The association of nocturia with cardiac disease, diabetes, body mass index, age and diuretic use: results from the BACH survey</article-title><source><italic>Journal of Urology</italic></source><year>2007</year><volume>177</volume><issue>4</issue><fpage>1385</fpage><lpage>1389</lpage><pub-id pub-id-type="pmid">17382738</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Michel</surname><given-names>MC</given-names></name><name><surname>Vrydag</surname><given-names>W</given-names></name></person-group><article-title>Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate</article-title><source><italic>British Journal of Pharmacology</italic></source><year>2006</year><volume>147</volume><fpage>S88</fpage><lpage>119</lpage><pub-id pub-id-type="pmid">16465187</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishihama</surname><given-names>H</given-names></name><name><surname>Momota</surname><given-names>Y</given-names></name><name><surname>Yanase</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>De Groat</surname><given-names>WC</given-names></name><name><surname>Kawatani</surname><given-names>M</given-names></name></person-group><article-title>Activation of <italic>&#x003b1;</italic> adrenergic receptors in the rat urothelium facilitates the micturition reflex</article-title><source><italic>Journal of Urology</italic></source><year>2006</year><volume>175</volume><issue>1</issue><fpage>358</fpage><lpage>364</lpage><pub-id pub-id-type="pmid">16406942</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hampel</surname><given-names>C</given-names></name><name><surname>Dolber</surname><given-names>PC</given-names></name><name><surname>Smith</surname><given-names>MP</given-names></name><etal/></person-group><article-title>Modulation of bladder <italic>&#x003b1;</italic>1-adrenergic receptor subtype expression by bladder outlet obstruction</article-title><source><italic>Journal of Urology</italic></source><year>2002</year><volume>167</volume><issue>3</issue><fpage>1513</fpage><lpage>1521</lpage><pub-id pub-id-type="pmid">11832780</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Takahashi</surname><given-names>S</given-names></name><name><surname>Zhong</surname><given-names>S</given-names></name><etal/></person-group><article-title>Function of the lower urinary tract in mice lacking <italic>&#x003b1;</italic>- adrenoceptor</article-title><source><italic>Journal of Urology</italic></source><year>2005</year><volume>174</volume><issue>1</issue><fpage>370</fpage><lpage>374</lpage><pub-id pub-id-type="pmid">15947692</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Alteration of the total IPSS (a), storage (b), voiding (c), postmicturition (domain for feeling of incomplete emptying) (d), and QOL (e) scores in men with dose escalation from 50&#x02009;mg/day to 70&#x02009;mg/day of naftopidil (75&#x02009;mg group) and those maintained with its 50&#x02009;mg/day (50&#x02009;mg group).</p></caption><graphic xlink:href="AU2011-804583.001a"/><graphic xlink:href="AU2011-804583.001b"/></fig><fig id="fig2" position="float"><label>Figure 2</label><caption><p>The rate of change in the QOL score (&#x00394;QOL) and each domain of the IPSS (&#x00394; each domain) with 50&#x02009;mg/day of naftopidil during the first 4 weeks.</p></caption><graphic xlink:href="AU2011-804583.002"/></fig><table-wrap id="tab1" position="float"><label>Table 1</label><caption><p>Patients' demographics and the baseline International Prostate Symptom Score (IPSS).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">
</th><th align="center" rowspan="1" colspan="1">Total</th><th align="center" rowspan="1" colspan="1">75&#x02009;mg group</th><th align="center" rowspan="1" colspan="1">50&#x02009;mg group</th><th align="center" rowspan="1" colspan="1">
<italic>P</italic> value</th></tr><tr><th align="left" rowspan="1" colspan="1">
</th><th align="center" rowspan="1" colspan="1">(<italic>n</italic> = 46)</th><th align="center" rowspan="1" colspan="1">(<italic>n</italic> = 35)</th><th align="center" rowspan="1" colspan="1">(<italic>n</italic> = 11)</th><th align="center" rowspan="1" colspan="1">(75&#x02009;mg versus 50&#x02009;mg)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, mean (years)</td><td align="center" rowspan="1" colspan="1">71.7 &#x000b1; 9.4</td><td align="center" rowspan="1" colspan="1">72.1 &#x000b1; 9.2</td><td align="center" rowspan="1" colspan="1">70.2 &#x000b1; 10.5</td><td align="center" rowspan="1" colspan="1">.559</td></tr><tr><td align="left" rowspan="1" colspan="1">Prostate volume, mean (mL)</td><td align="center" rowspan="1" colspan="1">31.7 &#x000b1; 24.8</td><td align="center" rowspan="1" colspan="1">34.6 &#x000b1; 24.9</td><td align="center" rowspan="1" colspan="1">25.0 &#x000b1; 24.8</td><td align="center" rowspan="1" colspan="1">.403</td></tr><tr><td align="left" rowspan="1" colspan="1">Residual urine, mean (mL)</td><td align="center" rowspan="1" colspan="1">24.0 &#x000b1; 41.5</td><td align="center" rowspan="1" colspan="1">24.5 &#x000b1; 43.3</td><td align="center" rowspan="1" colspan="1">22.4 &#x000b1; 36.1</td><td align="center" rowspan="1" colspan="1">.899</td></tr><tr><td align="left" rowspan="1" colspan="1">IPSS total</td><td align="center" rowspan="1" colspan="1">17.2 &#x000b1; 6.9</td><td align="center" rowspan="1" colspan="1">18.1 &#x000b1; 7.2</td><td align="center" rowspan="1" colspan="1">14.2 &#x000b1; 5.1</td><td align="center" rowspan="1" colspan="1">.100</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Storage score</td><td align="center" rowspan="1" colspan="1">7.7 &#x000b1; 3.5</td><td align="center" rowspan="1" colspan="1">7.8 &#x000b1; 3.6</td><td align="center" rowspan="1" colspan="1">7.5 &#x000b1; 3.3</td><td align="center" rowspan="1" colspan="1">.780</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Pollakisuria</td><td align="center" rowspan="1" colspan="1">3.0 &#x000b1; 1.6</td><td align="center" rowspan="1" colspan="1">3.1 &#x000b1; 1.6</td><td align="center" rowspan="1" colspan="1">2.8 &#x000b1; 1.8</td><td align="center" rowspan="1" colspan="1">.602</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Urgency</td><td align="center" rowspan="1" colspan="1">1.9 &#x000b1; 1.8</td><td align="center" rowspan="1" colspan="1">2.0 &#x000b1; 1.9</td><td align="center" rowspan="1" colspan="1">1.5 &#x000b1; 1.4</td><td align="center" rowspan="1" colspan="1">.469</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Nocturia</td><td align="center" rowspan="1" colspan="1">2.8 &#x000b1; 1.3</td><td align="center" rowspan="1" colspan="1">2.7 &#x000b1; 1.3</td><td align="center" rowspan="1" colspan="1">3.1 &#x000b1; 1.4</td><td align="center" rowspan="1" colspan="1">.385</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Voiding score</td><td align="center" rowspan="1" colspan="1">7.2 &#x000b1; 4.3</td><td align="center" rowspan="1" colspan="1">7.9 &#x000b1; 4.3</td><td align="center" rowspan="1" colspan="1">5.0 &#x000b1; 3.5</td><td align="center" rowspan="1" colspan="1">.051</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Intermittency</td><td align="center" rowspan="1" colspan="1">2.2 &#x000b1; 1.9</td><td align="center" rowspan="1" colspan="1">2.4 &#x000b1; 2.0</td><td align="center" rowspan="1" colspan="1">1.7 &#x000b1; 1.7</td><td align="center" rowspan="1" colspan="1">.334</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Slow stream</td><td align="center" rowspan="1" colspan="1">3.2 &#x000b1; 1.8</td><td align="center" rowspan="1" colspan="1">3.6 &#x000b1; 1.6</td><td align="center" rowspan="1" colspan="1">2.1 &#x000b1; 1.9</td><td align="center" rowspan="1" colspan="1">.013</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Straining</td><td align="center" rowspan="1" colspan="1">1.7 &#x000b1; 1.8</td><td align="center" rowspan="1" colspan="1">1.9 &#x000b1; 1.9</td><td align="center" rowspan="1" colspan="1">1.2 &#x000b1; 1.3</td><td align="center" rowspan="1" colspan="1">.242</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x02003;Postmicturition score*</td><td align="center" rowspan="1" colspan="1">2.3 &#x000b1; 1.8</td><td align="center" rowspan="1" colspan="1">2.5 &#x000b1; 1.9</td><td align="center" rowspan="1" colspan="1">1.7 &#x000b1; 1.6</td><td align="center" rowspan="1" colspan="1">.233</td></tr><tr><td align="left" rowspan="1" colspan="1">QOL score</td><td align="center" rowspan="1" colspan="1">4.8 &#x000b1; 1.0</td><td align="center" rowspan="1" colspan="1">4.9 &#x000b1; 1.0</td><td align="center" rowspan="1" colspan="1">4.6 &#x000b1; 1.1</td><td align="center" rowspan="1" colspan="1">.442</td></tr></tbody></table><table-wrap-foot><fn><p>Score: mean &#x000b1; standard deviation (SD); postmicturition score*, domain for feeling of incomplete emptying.</p></fn></table-wrap-foot></table-wrap></floats-group></article>